BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11784418)

  • 1. Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India.
    Dua VK; Sharma VP
    Ann Trop Med Parasitol; 2001 Oct; 95(7):655-9. PubMed ID: 11784418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy.
    Goller JL; Jolley D; Ringwald P; Biggs BA
    Am J Trop Med Hyg; 2007 Feb; 76(2):203-7. PubMed ID: 17297026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat.
    Srivastava HC; Sharma SK; Bhatt RM; Sharma VP
    Indian J Malariol; 1996 Dec; 33(4):173-9. PubMed ID: 9125831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia.
    Alvarez G; Piñeros JG; Tobón A; Ríos A; Maestre A; Blair S; Carmona-Fonseca J
    Am J Trop Med Hyg; 2006 Oct; 75(4):605-9. PubMed ID: 17038680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India.
    Yadav RS; Ghosh SK
    J Parasitol; 2002 Oct; 88(5):1042-4. PubMed ID: 12435158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine.
    Dao NV; Cuong BT; Ngoa ND; Thuy le TT; The ND; Duy DN; Dai B; Thanh NX; Chavchich M; Rieckmann KH; Edstein MD
    Trans R Soc Trop Med Hyg; 2007 Jun; 101(6):534-9. PubMed ID: 17368694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria.
    Khatri TD
    J Assoc Physicians India; 2002 Mar; 50():458-9. PubMed ID: 11922250
    [No Abstract]   [Full Text] [Related]  

  • 8. [Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment].
    Telgt DS; Mulder L; Dolmans WM
    Ned Tijdschr Geneeskd; 1997 Sep; 141(37):1783-6. PubMed ID: 9545728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
    Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.
    Kitchener S; Nasveld P; Edstein MD
    Am J Trop Med Hyg; 2007 Mar; 76(3):494-6. PubMed ID: 17360873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand.
    Hamedi Y; Safa O; Zare S; Tan-ariya P; Kojima S; Looareesuwan S
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):570-4. PubMed ID: 15689068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria.
    Gogtay NJ; Desai S; Kadam VS; Kamtekar KD; Dalvi SS; Kshirsagar NA
    J Assoc Physicians India; 2000 Nov; 48(11):1085-6. PubMed ID: 11310387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chloroquine sensitivity of Plasmodium vivax in Thailand.
    Looareesuwan S; Wilairatana P; Krudsood S; Treeprasertsuk S; Singhasivanon P; Bussaratid V; Chokjindachai W; Viriyavejakul P; Chalermrut K; Walsh D S; White J
    Ann Trop Med Parasitol; 1999 Apr; 93(3):225-30. PubMed ID: 10562823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence rate of vivax malaria in the Republic of Korea.
    Moon KT; Kim YK; Ko DH; Park I; Shin DC; Kim C
    Trans R Soc Trop Med Hyg; 2009 Dec; 103(12):1245-9. PubMed ID: 19041109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days.
    Carmona-Fonseca J; Maestre A
    Acta Trop; 2009 Nov; 112(2):188-92. PubMed ID: 19653988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections.
    Gogtay NJ; Desai S; Kamtekar KD; Kadam VS; Dalvi SS; Kshirsagar NA
    Ann Trop Med Parasitol; 1999 Dec; 93(8):809-12. PubMed ID: 10715673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.
    Nayar JK; Baker RH; Knight JW; Sullivan JS; Morris CL; Richardson BB; Galland GG; Collins WE
    J Parasitol; 1997 Aug; 83(4):739-45. PubMed ID: 9267419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment.
    Carmona-Fonseca J; Alvarez G; Maestre A
    Am J Trop Med Hyg; 2009 Feb; 80(2):188-93. PubMed ID: 19190211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse/reinfection patterns of Plasmodium vivax infection: a four year study.
    Prasad RN; Virk KJ; Sharma VP
    Southeast Asian J Trop Med Public Health; 1991 Dec; 22(4):499-503. PubMed ID: 1820634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A study of relapsed cases of vivax malaria after the standard primaquine therapy].
    Kimura M; Tomizawa I; Takizawa Y; Ohtomo H
    Kansenshogaku Zasshi; 1996 Oct; 70(10):1086-91. PubMed ID: 8952270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.